carmustine has been researched along with Dysmyelopoietic Syndromes in 12 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 5.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "A 42-year-old male patient with a history of occupational exposure to benzene presented with pancytopenia." | 3.69 | t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission. ( Mahendra, P; Marcus, RE; Nacheva, E; Richards, EM; Sinclair, P, 1996) |
| "Six patients, four with Hodgkin's disease and two with non-Hodgkin lymphomas, developed leukemic complications, myelodysplasia (MDS) in four cases and overt acute myeloid leukemia (AML) in two." | 2.68 | High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. ( Geisler, C; Myhre, J; Pedersen, M; Pedersen-Bjergaard, J, 1997) |
| " Alternative dosing regimens, such as 1-week on/1-week off, or 3-week on/1-week off, that deliver more prolonged exposure have been observed to result in higher cumulative doses than the standard 5-day regimen and may deplete tumor-derived O6-methylguanine-DNA methyltransferase (MGMT) in tumor cells, thus sensitizing tumor cells to the effects of TMZ." | 2.45 | [Treatment of glioma with temozolomide]. ( Nishikawa, R, 2009) |
| "Cytogenetic analysis showed complex chromosomal abnormalities including 11q23 rearrangement, which is frequently found in topoisomerase II inhibitor-related hematologic malignancies." | 1.31 | A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma. ( Bahng, HS; Jang, GD; Jeong, YH; Ji, HS; Kim, EK; Kim, SH; Kim, SW; Kim, WK; Lee, JS; Park, CJ; Park, IG; Suh, CW; Suh, EJ, 2002) |
| "Despite the fact that follicular lymphomas are both chemo- and radiosensitive, the disease is generally non-curable." | 1.31 | Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma. ( Berglund, A; Carlson, K; Enblad, G; Glimelius, B; Hagberg, H, 2000) |
| "Three hundred patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) were treated with cyclophosphamide, carmustine and etoposide and autologous stem cell support from 1986 through 1994." | 1.31 | Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). ( Antin, J; Ault, K; Elias, A; Ibrahim, J; Khurshid, A; Mauch, P; Wheeler, C, 2001) |
| "Hodgkin's disease is curable in the majority of patients, although a proportion of patients are resistant to or relapse after initial therapy." | 1.30 | High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. ( Devereux, S; Goldstone, AH; Gregory, W; Hancock, B; Harrison, CN; Hoskin, P; Hudson, GV; Linch, DC; MacMillan, AK; Milligan, D; Newland, AC; Winfield, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 4 (33.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishikawa, R | 1 |
| Montoto, S | 1 |
| Matthews, J | 1 |
| Greaves, P | 1 |
| Lillington, D | 1 |
| Anderson, D | 1 |
| Gribben, JG | 2 |
| Lister, TA | 1 |
| Jang, GD | 1 |
| Kim, SW | 1 |
| Suh, CW | 1 |
| Kim, EK | 1 |
| Bahng, HS | 1 |
| Jeong, YH | 1 |
| Park, IG | 1 |
| Kim, WK | 1 |
| Kim, SH | 1 |
| Suh, EJ | 1 |
| Park, CJ | 1 |
| Ji, HS | 1 |
| Lee, JS | 1 |
| Sirohi, B | 1 |
| Cunningham, D | 1 |
| Powles, R | 1 |
| Murphy, F | 1 |
| Arkenau, T | 1 |
| Norman, A | 1 |
| Oates, J | 1 |
| Wotherspoon, A | 1 |
| Horwich, A | 1 |
| Mahendra, P | 1 |
| Richards, EM | 1 |
| Sinclair, P | 1 |
| Nacheva, E | 1 |
| Marcus, RE | 1 |
| Pedersen-Bjergaard, J | 1 |
| Pedersen, M | 1 |
| Myhre, J | 1 |
| Geisler, C | 1 |
| Laughlin, MJ | 1 |
| McGaughey, DS | 1 |
| Crews, JR | 1 |
| Chao, NJ | 1 |
| Rizzieri, D | 1 |
| Ross, M | 1 |
| Gockerman, J | 1 |
| Cirrincione, C | 1 |
| Berry, D | 1 |
| Mills, L | 1 |
| Defusco, P | 1 |
| LeGrand, S | 1 |
| Peters, WP | 1 |
| Vredenburgh, JJ | 1 |
| Harrison, CN | 1 |
| Gregory, W | 1 |
| Hudson, GV | 1 |
| Devereux, S | 1 |
| Goldstone, AH | 2 |
| Hancock, B | 1 |
| Winfield, D | 1 |
| MacMillan, AK | 2 |
| Hoskin, P | 1 |
| Newland, AC | 1 |
| Milligan, D | 1 |
| Linch, DC | 2 |
| Berglund, A | 1 |
| Enblad, G | 1 |
| Carlson, K | 1 |
| Glimelius, B | 1 |
| Hagberg, H | 1 |
| Wheeler, C | 1 |
| Khurshid, A | 1 |
| Ibrahim, J | 1 |
| Elias, A | 1 |
| Mauch, P | 1 |
| Ault, K | 1 |
| Antin, J | 1 |
| Richards, JD | 1 |
| Lichtman, SM | 1 |
| Schulman, P | 1 |
1 review available for carmustine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
[Treatment of glioma with temozolomide].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2009 |
1 trial available for carmustine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality | 1997 |
10 other studies available for carmustine and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Myeloablative chemotherapy for chemo-sensitive recurrent follicular lymphoma: potential benefit in second relapse.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; | 2013 |
A case of treatment-related myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemotherapy with autologous stem cell transplantation for non-Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocy | 2002 |
Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2008 |
t(9;13)(q34;q12) chromosomal translocation persisting 4 years post autologous bone marrow transplantation for secondary AML despite morphological remission.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzene; Bone Marrow; Bone Mar | 1996 |
Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantat | 1998 |
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 1999 |
Long-term follow-up of autologous stem-cell transplantation for follicular and transformed follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Carmustine; Cataract; Co | 2000 |
Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; | 2001 |
Double autologous bone marrow transplantation in acute myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carm | 1989 |
Carmustine and myelodysplasia.
Topics: Aged; Carmustine; Chromosome Deletion; Chromosomes, Human, 4-5; Humans; Male; Myelodysplastic Syndro | 1985 |